



# Dr. med. Mathieu Chevallier

Medical oncology  
General Internal Medicine

---

## Languages

FR,EN

## Education

After completing his studies at the University of Geneva, Dr Chevallier specialised in general internal medicine and then in medical oncology. He is passionate about the management of oncological diseases and personalised treatments, with a rigorous scientific medical approach and the support of complementary therapies.

2022: FMH specialist title in oncology

2018: FMH specialist title in general medicine

2007 - 2011: University of Geneva, Federal Diploma in Medicine

2005: EPFL, Life Sciences and Technologies

## Work Experience

2022-2023 Clinical head of the oncology department at the HUG

2016-2023 Medical oncology, clinical research unit, inpatient and outpatient care  
Pre- and post-graduate medical teaching at the University of Geneva and Haute Ecole de Santé

2011-2016 Internal and general medicine (inpatient, outpatient, emergency, geriatrics)

## Memberships

- Swiss Society for Medical Oncology (SSOM)
- European Society for Medical Oncology (ESMO)
- Swiss Medical Association (FMH)
- Association of Doctors of the Canton of Geneva (AMGe)

## Publications

[Rare Synchronous Lung Cancers in a Nonsmoker with Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition Alterations: A Case Report.](#)

Baer X, **Chevallier M**, Rey Cobo J, Plojoux J, De Vito C, Addeo A. Case Rep Oncol. 2024 Apr 12;17(1):549-555. doi: 10.1159/000538019. eCollection 2024 Jan-Dec. PMID: 38618277

### [Pleural Mesothelioma in the Era of Immunotherapy](#)

**Chevallier M**, Kim F, Friedlaender A, Addeo A. Clin Med Insights Oncol. 2023 Jul 20;17:117955. doi: 10.1177/11795549231178173. eCollection 2023. PMID: 37492425

### [Immunodeficiency and Lymphoma in Jacobsen Syndrome.](#)

Nigolian H, Nieke JP, **Chevallier M**, Stathaki E, Sloan-Béna F, Carminho-Rodrigues MT, Jandus P. J Investig Allergol Clin Immunol. 2022 Oct 11;32(5):408-409. doi: 10.18176/jiaci.0777. Epub 2022 Jan 14. PMID: 35029149

### [Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.](#)

**Chevallier M**, Borgeaud M, Addeo A, Friedlaender A. World J Clin Oncol. 2021 Apr 24;12(4):217-237. doi: 10.5306/wjco.v12.i4.217. PMID: 33959476

### [The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy.](#)

Friedlaender A, Tsantoulis P, **Chevallier M**, De Vito C, Addeo A. Front Oncol. 2021 Mar 30;11:644472. doi: 10.3389/fonc.2021.644472. eCollection 2021. PMID: 33869038

### [Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.](#)

**Chevallier M**, Tsantoulis P, Addeo A, Friedlaender A. Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):597-603. doi: 10.21873/cgp.20216. PMID: 32859638

### [Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review.](#)

**Chevallier M**, Chevallier-Lugon C, Friedlaender A, Addeo A. Case Rep Oncol. 2021 Mar 2;14(1):279-283. doi: 10.1159/000513492. eCollection 2021 Jan-Apr. PMID: 33776717

### [\[The general practitioner: an essential actor to ensure a specific management in oncologic patients\].](#)

**Chevallier M**, Chevallier-Lugon C, Pernin T. Rev Med Suisse. 2019 Jun 5;15(654):1188-1192. PMID: 31166671 French.

## Accreditation

[Clinique Générale-Beaulieu](#)

## Specialties

[Oncology](#)

[Internal medicine](#)

## Contact

**Générale-Beaulieu Swiss Oncology Network**

Chemin de Beau-Soleil 20

1206 Genève

T 022 839 57 98

[cabinet.chevallier@beaulieu.ch](mailto:cabinet.chevallier@beaulieu.ch)

[Download vCard](#)